We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

MaxCyte

Second CRADA with the NIH to advance CRISPR therapies

Lighthouse | 11 June 2018

Bonesupport

More than just bridging a gap

Initiation | 06 June 2018

BerGenBio

Another major opportunity arises

Update | 09 May 2018

Karolinska Development

Portfolio progress validates investment philosophy

Outlook | 03 May 2018

e-therapeutics

Parkinson’s disease collaboration with C4X Discovery

Lighthouse | 01 May 2018

BerGenBio

Capital raised as new opportunities open up

Lighthouse | 16 April 2018

MaxCyte

Another year of strong delivery as CARMA approaches the clinic

Lighthouse | 04 April 2018

e-Therapeutics

A lean and mean drug discovery machine

Lighthouse | 27 March 2018

BerGenBio

Recruitment to first stage of TNBC Phase II completed ahead of schedule

Lighthouse | 19 February 2018

BerGenBio

Funded to achieve multiple value inflection points

Update | 15 February 2018
1 2 3 4 5 6 7 8 9 10 11 12 13 14
136 results found.